多西紫杉醇联合替吉奥治疗晚期胃癌的临床观察

Docetaxel in combination with S1 in the treatment of patients with advanced gastric cancer

目的观察多西紫杉醇联合替吉奥治疗晚期胃癌的临床疗效及不良反应。方法将84例晚期胃癌患者随机分为实验组和对照组，每组42例。试验组接受多西紫杉醇75mg／m2静脉滴注，第1天，替吉奥80mg／m2，分2次，餐后口服。第1，14天，21d为1个周期，至少化疗2个周期；对照组化疗方案为顺铂25mg／m2，静脉滴注，第1～3天，醛氢叶酸钙200mg／m2，静脉滴注，第l～5天，5一氟尿嘧啶500mg／m2，第l～5天（在cF之后），28d为1个周期，至少化疗2个周期。评价两组疗效及不良反应。结果试验组有效率为57．1％，中位疾病进展时间9．3个月，中位生存期14．3个月，1、2年生存率分别为57．1％和21．4％；对照组有效率为42．9％，中位疾病进展时间6．1个月，中位生存期10．2个月，1、2年生存率分别为38．1％和9．5％。两组疗效差异有统计学意义（P〈0．05）。主要毒副反应为骨髓抑制和胃肠道反应，大部分患者可耐受。结论多西紫杉醇联合替吉奥治疗晚期胃癌的近期疗效好，且不良反应可以耐受，值得进一步研究。

Objective To evaluate the efficacy and toxicity of docetaxel combined with S1 capsule in the treatment of advanced gastric cancer patients. Methods Group A： The 42 patients with advanced gastric cancer were treated with docetaxel 75 mg/m2 on day 1 and S1 capsule 80 mg/m2 twice day for 14 days, The chemotherapy repeated every 3 weeks. Efficacy and toxicities were evaluated after at least 2 cycles of chemotherapy. Group B： 42 patients received Cisplatin（DDP） 25 mg/m2, d 1-3,CF 200 mg/m2, d1-5 iv, 5-Fu 500 mg/m2, d1-5, each cycle 4 weeks. Results The overall response rate of Group A was 57.1% and the overall response rate of Group B was 42.9%, Median time to progress （TFP） was 9.3 months in Group A and 6.1 months in Group B, median survival time （MST） was 14.3 months in Group A and 10.2 months in Group B. There was significantly difference between two group （P〈0.05）.The main adverse reactions were leueopenia, nausea and vomiting, which can be tolerated by most of the patients. Conclusion The combination of docetaxel and S1 is well tolerated and effective in the treatment of patients with advanced gastric cancer.